FDA grants Opdivo breakthrough status for kidney cancer
September 18, 2015Research and Development, Sales and Marketing BMS, Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, Kidney cancer, immuno-oncology, immunotherapy, nivolumab, opdivo, renal cell carcinoma
The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment. The FDA’s decision …
Bedrock Healthcare communications appoints new head of med comms
September 18, 2015Medical Communications Andy Grigg, Bedrock
Andy Grigg has joined Bedrock Healthcare Communications as head of medical communications. Grigg joins from Inspired Science where he was practice …
Report identifies digital trends in life sciences industry
September 18, 2015Medical Communications digital, disruptive innovations, disruptive technologies, innovation, life sciences
The life sciences industry will be subject to major disruption from five key trends over the coming years, a report …
Number of mobile health apps quadruples in two years
September 18, 2015Medical Communications apps, clinical trials, communications, digital, mhealth, technology
The number of mobile health applications available to consumers has reached more than 165,000, as the industry for sensors and …
UK second in global innovation index
September 18, 2015Medical Communications, Research and Development Global Innovation Index, World Intellectual Property Organisation, innovation, intellectual property, patents, wipo
The UK – along with Switzerland, Sweden, the Netherlands and the US – is in the world’s five most innovative …
Jamie McGarvey joins Astellas Pharma communications team
September 18, 2015Medical Communications Astellas, Astellas Pharma, Jamie McGarvey
Astellas Pharma has appointed Jamie McGarvey as senior manager of employee communications within its corporate affairs department. McGarvey will be …
Sandoz opens €150m manufacturing facility
September 18, 2015Manufacturing and Production Austria, BioInject, Novartis, Sandoz
Sandoz has opened a €150m state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria. Known as BioInject will result in the creation …
AstraZeneca and US Government collaborate to develop new antibiotics
September 17, 2015Research and Development AstraZeneca, Azactam, BARDA, Department of Health and Human Services, HHHS, avibactam, aztreonam
AstraZeneca has entered into a public-private partnership with the US Department of Health and Human Services to develop drugs to …
Astellas Pharma EMEA appoints new chief financial officer
September 17, 2015Sales and Marketing Astellas, Eugene Van Rensburg
Astellas Pharma Europe, Middle East and Africa has appointed Eugene Van Rensburg to the position of chief financial officer, from …
NICE says Celgene’s Abraxane is ‘too expensive for pancreatic cancer’
September 17, 2015Sales and Marketing Abraxane, Celgene, NICE, Pancreatic cancer
NICE has decided not to recommend Abraxane (nab-paclitaxel) by Celgene in combination with gemcitabine for adults with metastatic pancreatic cancer.In …
PMPCA rules on multiple pharma code breaches
September 17, 2015Medical Communications, Sales and Marketing ABPI, ABPI Code, PMCPA, Prescriptions Medicine Code of Practice Authority
The industry’s code of conduct regulator has ruled on several alleged breaches of the ABPI code of pharmaceutical conduct by …
Cancer Drugs Fund ‘not sustainable in current form’
September 17, 2015CDF, Cancer Drugs Fund, Department of Health, NHS England, National Audit Office, Public Accounts Committe, Roche, avastin
The Cancer Drugs Fund has improved access to treatments, although the UK still lags behind other countries despite its ‘unsustainable’ …
Amgen joins M&A rush with deals for Dezima and Xencor
September 16, 2015Research and Development, Sales and Marketing Amgen, Cancer, Denzime, Xencor, cardiovascular disease, high cholesterol, inflammation
Amgen has struck deals that could potentially be worth $3.25 billion, to purchase the Dutch firm Dezima and kick-off a …
NICE rejects Farydak for multiple myeloma
September 16, 2015Sales and Marketing Farydak, NICE, Novartis, multiple myeloma, panobinostat
NICE has rejected Novartis Farydak in its draft guidance, ruling it out as a treatment for multiple myeloma. Farydak (panobinostat) is …
Cancers diagnosed earlier in England, but cases rise
September 16, 2015Cancer, Jeremy Hunt, Public Health England, cancer diagnosis, public health
The proportion of cancers diagnosed by GPs under the ‘two-week wait’ referral pathway rose, and late diagnoses fell, after the …
President Obama nominates Dr Robert Califf as new FDA head
September 16, 2015Manufacturing and Production, Medical Communications
US President Barack Obama has put forward Dr Robert Califf as the next commissioner of the FDA, according to a …
Sanofi’s LixiLan meets target in Phase III diabetes trial
September 16, 2015Research and Development Lantus, LixiLan, Lixisenatide, Lxyumia, Sanofi, diabetes, insulin glargine, metformin, type 2 diabetes
Sanofi’s Phase III clinical trial of its Lixilan treatment has achieved its primary endpoint in patients with type 2 diabetes, …
The biggest side-effect of making medicine
September 16, 2015Research and Development evergreening, intellectual property, patent
International intellectual property regulations are doing serious damage to the pharmaceutical industry and, by extension, to the health of people …
R&D firms team up to tackle antibiotic resistance
September 16, 2015Research and Development AMR, Antibiotics, Jim O'Neill, O'Neill review, antimicrobial resistance, drug development
Two companies at the centre of the UK’s R&D efforts to tackle the growing threat of resistance to antibiotics are expanding …
AstraZeneca scores positive real-world Forxiga data
September 16, 2015Research and Development AstraZeneca, EASD, European Association for the Study of Diabetes, Forxiga, dapagliflozin, exenatide, real world data, real world evidence
The real-world study of AstraZeneca’s diabetes drug Forxiga has found its use in UK patients primary care patients supports the …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
